Advertisement

 

 

Chronic hepatitis B virus and liver fibrosis: A mathematical model.

Chronic hepatitis B virus and liver fibrosis: A mathematical model.
Author Information (click to view)

Friedman A, Siewe N,


Friedman A, Siewe N, (click to view)

Friedman A, Siewe N,

Advertisement

PloS one 2018 04 1013(4) e0195037 doi 10.1371/journal.pone.0195037

Abstract

Hepatitis B virus (HBV) infection is a liver disorder that can result in cirrhosis, liver failure and hepatocellular carcinoma. HBV infection remains a major global health problem, as it affects more 350 million people chronically and kills roughly 600,000 people annually. Drugs currently used against HBV include IFN-α that decreases viremia, inflammation and the growth of liver fibrosis, and adefovir that decreases the viral load. Each of these drugs can have severe side-effects. In the present paper, we consider the treatment of chronic HBV by a combination of IFN-α and adefovir, and raise the following question: What should be the optimal ratio between IFN-α and adefovir in order to achieve the best ‘efficacy’ under constraints on the total amount of the drugs; here the efficacy is measured by the reduction of the levels of inflammation and of fibrosis? We develop a mathematical model of HBV pathogenesis by a system of partial differential equations (PDEs) and use the model to simulate a ‘synergy map’ which addresses the above question.

Submit a Comment

Your email address will not be published. Required fields are marked *

20 + thirteen =

[ HIDE/SHOW ]